First Time Loading...

Coherus BioSciences Inc
NASDAQ:CHRS

Watchlist Manager
Coherus BioSciences Inc Logo
Coherus BioSciences Inc
NASDAQ:CHRS
Watchlist
Price: 2.235 USD -1.54%
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

CHRS Price Targets Summary
Coherus BioSciences Inc

Wall Street analysts forecast CHRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CHRS is 10.637 USD with a low forecast of 4.04 USD and a high forecast of 24.15 USD.

CHRS Lowest Forecast
Wall Street Target
4.04 USD
81% Upside
CHRS Average Forecast
Wall Street Target
10.637 USD
376% Upside
CHRS Highest Forecast
Wall Street Target
24.15 USD
981% Upside
Lowest
Price Target
4.04 USD
81% Upside
Average
Price Target
10.637 USD
376% Upside
Highest
Price Target
24.15 USD
981% Upside
Coherus BioSciences Inc Competitors:
Price Targets
SOBI
Swedish Orphan Biovitrum AB (publ)
25% Upside
Y
YS
YS Biopharma Co Ltd
478% Upside
I
TIL
Instil Bio Inc
150% Upside
6160
Beigene Ltd
38% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
25% Upside
Y
YS
YS Biopharma Co Ltd
478% Upside
I
TIL
Instil Bio Inc
150% Upside
6160
Beigene Ltd
38% Upside
VYGR
Voyager Therapeutics Inc
105% Upside
PRQR
ProQR Therapeutics NV
114% Upside
300685
Amoy Diagnostics Co Ltd
29% Upside
ENLV
Enlivex Therapeutics Ltd
341% Upside

Revenue
Forecast

Revenue Estimate
Coherus BioSciences Inc

For the last 8 years the compound annual growth rate for Coherus BioSciences Inc's revenue is 31%. The projected CAGR for the next 3 years is 22%.

31%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Coherus BioSciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Coherus BioSciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-42%
Average Miss
What are analyst estimates?

See Also

Summary
CHRS intrinsic value, competitors valuation, and company profile.
DCF Valuation
CHRS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CHRS stock valuation using valuation multiples.
Wall Street Estimates
CHRS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CHRS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CHRS's stock price target?
Price Target
10.637 USD

According to Wall Street analysts, the average 1-year price target for CHRS is 10.637 USD with a low forecast of 4.04 USD and a high forecast of 24.15 USD.

What is Coherus BioSciences Inc's Revenue forecast?
Projected CAGR
22%

For the last 8 years the compound annual growth rate for Coherus BioSciences Inc's revenue is 31%. The projected CAGR for the next 3 years is 22%.

ALPHA SPREAD
Join more than 134,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.